Once a futuristic concept, asset tokenization is now a tangible reality. Major platforms are integrating tokenized versions of traditional assets like U.S. stocks, gold, and Treasury bonds, blurring the lines between crypto and conventional finance and enabling 24/7 trading.
Amid global market uncertainty, savvy investors are shifting focus to Asia's resilient technology sector, where companies like Optowide Technologies, Zhejiang Century Huatong, and Digital Garage are demonstrating robust innovation and growth potential despite broader economic headwinds.
Amidst record market levels, analysts highlight a select group of companies—from AI leaders to emerging fintech—with strong fundamentals and room for significant expansion.
As Fortive prepares to release its fourth-quarter results, investors are weighing slowing revenue growth projections against a backdrop of robust peer performance and cautious analyst sentiment. The industrial technology firm's ability to meet or exceed forecasts could signal its resilience in a fluctuating market.
As Vishay Intertechnology prepares to release its fourth-quarter results, investors are weighing the chipmaker's recent performance against a backdrop of industry-wide gains and mixed signals from peers.
As the RBA's policy decisions loom, investors are scouring the market for resilient opportunities. We spotlight three ASX-listed penny stocks—Aura Energy, Beam Communications, and Count Limited—each with a market cap over A$10 million, offering a blend of high-risk potential and strategic positioning in their respective sectors.
Universal Technical Institute (NYSE: UTI) is scheduled to release its fourth-quarter earnings after Wednesday's market close. Investors are watching for signs of sustained growth in the vocational education sector as economic conditions shift.
While flashy jets and missiles capture public attention, L3Harris Technologies operates in the critical, unseen layers of connectivity and electronic warfare. As global tensions and technological threats evolve, its role as a foundational enabler of next-generation defense systems is driving a compelling investment thesis centered on resilience and information dominance.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
As AI infrastructure scales, reliability becomes paramount. Credo Technology Group, once a niche connectivity player, is now seeing explosive growth as its solutions become critical to preventing costly failures in hyperscale data centers. With revenue soaring over 270% and margins expanding, the debate is whether Credo is a cyclical beneficiary or the foundational 'toll road' of modern AI computing.
Criteo S.A. (NASDAQ: CRTO), the ad-tech firm, is trading at near-historic low valuations, sparking a debate among value investors. While its legacy business faces well-documented headwinds, its growing Retail Media segment and aggressive capital returns present a potential asymmetric opportunity, according to a bullish thesis gaining traction online.
Kforce reports stronger-than-expected Q4 2025 results, citing the highest sequential growth in its tech business since 2022. The company sees early signs of a market recovery, fueled by client demand for flexible talent to tackle AI-driven projects and foundational IT work.
Investment firm Hussman Strategic Advisors has liquidated its entire stake in TG Therapeutics, a move that comes as the biotech's stock lags behind broader market gains despite reporting strong revenue growth for its flagship product.
Amid surging government revenue and public protests over its ICE contracts, Palantir CEO Alex Karp defends the company's controversial surveillance technology, framing it as a safeguard against state overreach rather than an enabler.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
As the ASX braces for a turbulent February amid rate hike fears, a closer look reveals resilient micro-caps with unique value propositions. We analyze three sub-$150M companies—from healthcare tech to critical minerals—that are navigating the volatility with strong balance sheets and niche market positions.
With interest rate uncertainty and global headwinds buffeting markets, income-focused investors are turning to dividend-paying stocks for potential stability. We examine three ASX-listed companies offering yields above 3%, assessing their resilience in the current climate.
Arlo Technologies has registered over 4.2 million shares for an employee stock plan, a move that brings potential dilution and the company's capital strategy into focus as its stock shows signs of cooling momentum after a strong run.
As the seasonal spectacle of Groundhog Day passes, the Nasdaq faces a more substantive test. With tech earnings under a microscope and macroeconomic uncertainty lingering, investors are weighing robust historical patterns against near-term caution.
U.S. equities edged higher Monday, buoyed by a rebound in semiconductor and AI infrastructure stocks, alongside a surge in rare earth companies following a new strategic initiative. Gains were tempered by falling energy shares, cryptocurrency volatility, and ongoing concerns over a partial government shutdown.
